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Objectives: The first objective was to determine the effect of inherited 
differences in the classic pathway complement protein C4 on complement 
activation by heparin-protamine complexes in cardiac surgery. Specifically, 
we hypothesized that patients with heterozygous C4A null phenotype 
(AOBB), who have decreased amounts of C4A, may have increased comple- 
ment activation because of reduced clearance of heparin-protamine com- 
plexes. The second objective was to determine whether heparin-protamine- 
induced complement activation correlated with postoperative pulmonary 
shunt fractions. Methods: C4 typing was performed by agarose gel immuno- 
fixation and crossed immunoelectrophoresis. Complement activation was 
measured by radioimmunoassay of C3a and C4a before cardiopulmonary 
bypass, after bypass, and after protamine infusion. Shunt fractions were 
calculated from blood gases. Results: Of the 79 patients, 18 expressed 
heterozygous C4A null allele (AOBB), 16 had heterozygous C4B null allele 
(AAB0), three had homozygous C4B null alleles (AA00), and the rest 
expressed both C4A and C4B alleles (AABB). Patients with heterozygous 
C4A null allele had significantly increased plasma levels of C4a after 
protamine neutralization of heparin (C4a of 2862 - 375 ng/ml; mean + 
standard error of the mean) when compared with patients with normal 
expression of C4 alleles (AABB) (C4a of 1580 -+ 141 ng/ml) or heterozygous 
C4B null allele (C4a 1526 - 208 ng/ml). Pulmonary shunt fractions 
obtained after the operation correlated with the classic pathway comple- 
ment activation by heparin-protamine complexes, but not with alternative 
pathway complement activation during cardiopulmonary b pass. Conclu- 
sions: Patients with heterozygous C4A null phenotype have increased 
complement activation by heparin-protamine complexes during cardiac 
operations, possibly because of their defective clearance. The classic 
pathway complement activation by heparin-protamine interaction corre- 
lates with postoperative pulmonary shunt fractions. (J Thorac Cardiovasc 
Surg 1997;114:482-8) 
C omplement is activated by two distinct mecha- nisms during cardiac operations. It is activated 
by the alternative pathway during the cardiopulmo- 
nary bypass (CPB) procedure 1 and by the classic 
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pathway during protamine neutralization of circu- 
lating heparin at the end of CPB. z' 3 Previous tudies 
show significant variations in complement activation 
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though these variations can be due to as yet unde- 
fined perioperative factors, they may also reflect the 
differences in the ability of individual patients to 
activate complement in response to heparin-prota- 
mine complexes. Heparin-protamine complexes 
have similarities to immune complexes 4' s by virtue 
of the fact that they both activate complement by 
the classic pathway. Thus it is possible that inherited 
differences in an early-acting classic pathway com- 
plement component may account for this variability. 
The fourth component of human complement 
plays a pivotal role in the classic pathway of com- 
plement activation and, thereby, also in the clear- 
ance of immune complexes. 6 The human C4 gene is 
coded at two different loci in the major histocom- 
patibility complex on chromosome 6, and the major 
products of these loci are designated C4A and C4B. 7 
These two major isotypes (C4A and C4B) differ in 
their biochemical and functional properties,  with 
activated C4B having more hemolytic activity and 
activated C4A binding more to immune complexes. 
The C4 gene also displays significant polymorphism 
with expression of a null allele at the C4A site and 
C4B site occurring in approximately 20% and 23% 
of the population, respectively. 7 Presence of a null 
allele (i.e., only a single copy of the active gene at 
either site) can be detected by crossed immunoelec- 
trophoresis as approximately 50% reduction in that 
particular protein. 9Because the binding of activated 
C4 is important in clearance of immune complexes, 
partial deficiency of the C4A, which preferentially 
binds to these complexes, can retard their clear- 
ance. 6 The similarities between heparin-protamine 
complexes and immune complexes in terms of pref- 
erential activation of the classic pathway led us to 
examine the correlation between C4 phenotypes and 
the degree of complement activation seen in CPB 
and protamine neutralization of heparin. The de- 
gree of complement activation during CPB and that 
resulting from heparin-protamine interaction was 
also correlated with the postoperative pulmonary 
shunt fractions. 
Patients, materials, and methods 
After we had obtained approval by the institutional 
review board and informed consent from the patients, 
patients undergoing CPB for first-time coronary artery 
bypass grafting were entered in this case series. Inclusion 
criteria included normal preoperative arterial blood gases 
and renal function, as well as a cardiac ejection fraction of 
45% or more. Patients were excluded if they had com- 
bined valvular and coronary artery disease or a history of 
myocardial infarction within the preceding 6 months. 
Anesthesia was induced with sufentanil, pancuronium, 
and midazolam with patients breathing 100% oxygen. 
Porcine heparin at a dose of 300 units/kg body weight was 
administered before institution of CPB. Additional 3000- 
to 5000-unit supplements of heparin were given to main- 
tain the activated clotting time over 400 seconds as 
measured by a Sonoclot analyzer (Sienco, Inc., Morrison, 
Colo.). Myocardial protection was achieved with hypo- 
thermic crystalloid potassium cardioplegic solution and 
topical cold saline slush to maintain myocardial tempera- 
tures between 10 ° and 15 ° C. Cobe membrane oxygenators 
(Cobe Laboratories, Inc., Lakewood, Colo.) were used in 
all cases. On completion of the CPB procedure, prota- 
mine sulfate (10 mg for every 1000 units of heparin) was 
diluted in 100 ml of 5% dextrose and administered over 
7.7 -+ 2.4 minutes (mean -+ standard deviation) via a 
peripheral vein. 
Blood samples for C3a des Arg (C3a) and C4a des Arg 
(C4a) were obtained in tubes containing ethylenediami- 
netetraacetic a id before institution of CPB, at the end of 
CPB but before protamine infusion, and 10 minutes after 
protamine infusion. Blood samples were centrifuged at 
4 ° C and plasma retrieved within 30 minutes of procure- 
ment. C3a and C4a assays were carried out with the use of 
radioimmunoassay kits from Amersham (Rockford, Ill.) 
per the manufacturer's in tructions. All assays were done 
in triplicate, with the variation in results among triplicates 
being less than 10%. 
C4 isotype studies were performed from plasma sam- 
ples obtained before the operation in tubes containing 
ethylenediaminetetraacetic acid according to previously 
described techniques. 1° Isotypes were assigned by com- 
parison to standards of known C4 isotypes according to 
accepted nomenclature] 1 Null alleles were inferred by the 
reduction in the density of corresponding C4A or C4B 
band and confirmed in all cases by crossed immunoelec- 
trophoresis performed according to previously described 
methods. 9 
Performing family studies to further define C4 pheno- 
types is not feasible in this older patient population. The 
methods used in our study allow us to identify single or 
double null alleles if they are confined to either the C4A 
or C4B locus. However, the simultaneous single null 
alleles at both loci (i.e., one C4AQ0 and one C4BQ0), 
which occur in approximately 3% of subjects, cannot be 
distinguished from a normal C4 phenotype without null 
alleles. Thus five possible C4 phenotype groups were 
deducible, which for convenience we have abbreviated as 
follows: (1) AABB = no detectable null alleles, (2) 
AOBB = a single null allele (heterozygous) at C4A locus, 
(3) 00BB = a homozygous C4A null allele, (4) AAB0 = a 
single null allele (heterozygous) at C4B locus, and (5) 
AA00 = a homozygous C4B null allele. A and B in the 
preceding refer to any expressed allele of the respective 
isotype (i.e., A represents A1 through A6 and B repre- 
sents B1, B2, or B3). 
As a measure of postoperative pulmonary function, 
physiologic (pulmonary) shunt fractions were calculated 
from arterial and mixed venous blood gases obtained 6 to 
8 hours and 16 to 18 hours after the operation. 12 
Differences with respect to C4a and C3a were evaluated 
by means of one-way analysis of variance separately for 
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Baseline Pre-Protamine Post-Protamine 
Fig. 1. Influence of C4 phenotype on complement acti- 
vation during cardiac operations as measured by C4a des 
Arg. C4a levels were measured at different time periods 
shown on the X axis; the baseline represents measure- 
ments before CPB, pre-protamine indicates measurements 
at the end of CPB but before protamine, and post- 
protamine reflects the measurements obtained from blood 
samples collected 10 minutes after protamine administra- 
tion. The triangular symbols joined by dashed lines repre- 
sent patients with normal C4 phenotype (AABB), open 
circles with solid lines represent patients with single C4A 
null allele (AOBB), and square symbols with dotted lines 
show the data on patients with single C4B null allele 
(AAB0). The error bars for each data point represent 
standard error of mean. The post-protamine C4a levels 
for the AOBB group were statistically different from those 
of the other two groups (see text). 
the pre-protamine and post-protamine sampling times. 
The Scheff6 multiple comparison procedure was used to 
detect differences between the C4 isotype groups. To 
better control for type I errors caused by performing tests 
at two different time points, we used a significance l vel of 
2.5%. A determination f the possible influence of other 
factors uch as protamine dose, CPB time, age, and body 
surface area was also investigated by means of analysis of 
covariance with these factors as covariates. The strength 
of the association between shunt fractions and change in 
C4a and C3a was assessed by Pearson's product moment 
correlation coefficient. The possibility that other factors 
could account for the association between shunt fractions 
and C4a was assessed by determining the partial correla- 
tion coefficients. We adjusted for a number of factors, 
including age, protamine dose, CPB time, and body 
surface area. Statistical analyses were performed with 
SPSS for Windows (version 6.1.3, SPSS Inc., Chicago, Ill.). 
Descriptive statistics are expressed as mean ± standard 
deviation. For group comparisons, the mean ± standard 
error of the mean and 95% confidence intervals (CI) are 
provided. 
Results 
Of the 79 patients entered in the study, 54 were 
male and 25 were female. Their mean age (_+ standard 
deviation) was 62.94 _+ 9 years, they were supported by 
CPB for 80.0 _+ 33.4 minutes, and they received 
288.4 _+ 71.1 mg of protamine. These parameters were 
not different among the C4 isotypes groups described 
herein. Only one patient required mechanical ventila- 
tion for greater than 24 hours. 
As described in the Patients, materials, and meth- 
ods section, C4 isotype studies were performed in all 
the patients in the study. Of these, 42 patients had 
no null alleles (AABB) (53.16%), 18 patients had 
one C4A null allele (AOBB) (22.78%), 16 patients 
had one C4B null allele (AAB0) (20.25%), and 
three patients had homozygous C4B null phenotype 
(AA00)(3.8%). None of the patients in the study 
had homozygous C4A null phenotype (00BB). Be- 
cause of the small number of patients, the homozy- 
gous C4B null group has not been included in the 
statistical analysis. Our results are comparable with 
previously reported phenotype frequencies. Awdeh 
and Alper, 7 in a comparable general population, 
found 20% frequency of one C4A null allele, 23% of 
one C4B null allele, 1% for both C4A null alleles, 
and 2% for both C4B null alleles. 
Complement activation by the classic pathway 
leads to an increase in both C3a and C4a, whereas 
alternative pathway activation is reflected by in- 
crease in C3a alone without corresponding increase 
in C4a. Figs. 1 and 2 show complement activation 
during cardiac operations as measured by C4a and 
C3a levels, respectively, in patients with different C4 
phenotypes. The baseline C3a and C4a levels were 
similar in the three C4 isotype groups. Levels of C3a 
and C4a at the end of CPB but before protamine 
infusion were evaluated. C3a levels (Fig. 2) in- 
creased in all three groups, without a corresponding 
degree of change in C4a (Fig. 1), indicating comple- 
ment activation predominantly by the alternative 
pathway during CPB. Protamine administration, on 
the other hand, led to increases in both C3a and C4a 
levels. As shown in Fig. 1, the post-protamine C4a 
levels were 1580 _+ 141 ng/ml (mean _+ standard 
error of the mean; 95% CI: 1295 to 1865 ng/ml) for 
the group with both C4 phenotypes present in full 
(AABB), 2862 _+ 375 ng/ml (95% CI: 2069 to 3654 
ng/ml) for the group with heterozygous C4A null 
phenotype (AOBB), and 1526 _+ 208 ng/ml (95% CI: 
1079 to 1974 ng/ml) for the group with heterozygous 
C4B null allele. The outcome of the Scheff6 multiple 
comparison procedure (at the 2.5% level of signifi- 
cance) indicates that the post-protamine C4a levels 
in patients with C4 phenotype AOBB were signifi- 
cantly higher than those of the group with C4 AABB 
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Baseline Pre-protamine Post-Protamine 
Fig. 2. Influence of C4 phenotype on complement acti- 
vation during cardiac operations as measured by C3a des 
Arg. C3a levels were measured at different ime periods 
shown on the X axis; the baseline represents measure- 
ments before CPB, pre-protamine indicates measurements 
at the end of CPB but before protamine, and post- 
protamine reflects the measurements obtained from blood 
samples collected 10 minutes after protamine administra- 
tion. The triangular symbols joined by dashed lines repre- 
sent patients with normal C4 phenotype (AABB), open 
circles with solid lines represent patients with single C4A 
null allele (AOBB), and square symbols with dotted lines 
show the data on patients with single C4B null allele 
(AAB0). The error bars for each data point represent 
standard error of mean. Although C3a levels increased at 
the pre-protamine and the post-protamine time points, 
the differences between the patient groups did not reach 
significance (see text). 
and the group with C4 AAB0 phenotype. No differ- 
ence was noted between the latter two groups. 
Furthermore, patient age, body surface area, prota- 
mine dose, and CPB time had no influence on the 
aforementioned conclusions. Potential misclassifica- 
tion of two patients (3% incidence of AOB0) of the 
AABB group would not have altered these conclu- 
sions even if these patients had the lowest C4a levels 
of the AABB group. 
The C3a levels after protamine infusion for the 
three groups were 4667 _+ 360 ng/ml (95% CI: 3939 
to 5394 ng/ml) for the group with a complete set of 
C4 alleles, 6152 +_ 707 ng/ml (95% CI: 4661 to 7643) 
for the group with heterozygous C4A null pheno- 
type, and 5548 _+ 677 ng/ml (95% CI: 4105 to 6992 
ng/ml) for the group with heterozygous C4B null 
phenotype. Although the group with C4A null phe- 
notype tended to have higher levels of C3a, signifi- 
cant differences among the three groups were not 
detected when subjected to the Scheff6 multiple 
comparison procedure. 
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Fig. 3. Effect of complement activation during heparin- 
protamine interaction on postoperative pulmonary shunt 
fraction: Pulmonary shunt fractions were calculated from 
arterial and mixed venous blood gases 16 to 18 hours after 
the operation and correlated with complement activation 
by heparin-protamine teraction as measured by change 
in C4a levels resulting from protamine administration 
(i.e., difference in C4a levels before and after protamine). 
The solid line represents he regression line of the associ- 
ation (r = 0.473; p = 0.0001). 
The clinical parameters of physiologic (pulmo- 
nary) shunt fractions were calculated in each patient 
from arterial and mixed venous blood gases ob-.  
tained 6 to 8 hours and 16 to 18 hours after the 
operation. Fig. 3 shows the results of pulmonary 
shunt fractions 16 to 18 hours after surgery, plotted 
against he rise in C4a levels caused by protamine 
infusion (i.e., the difference in C4a levels after 
protamine and one obtained at the end of CPB 
before protamine administration). As shown, a cor- 
relation existed between the two parameters (r = 
0.47, p = 0.0001). After we had controlled for age, 
body surface area, dose of protamine, and CPB 
time, the correlation coefficient was similar (r = 
0.49). Similarly, shunt fractions at this time period 
correlated with the absolute C4a levels after prota- 
mine administration (r = 0.43, p = 0.001). There 
was also a correlation between the shunt fractions 
obtained 6 to 8 hours after the operation with both 
the C4a levels (r = 0.34, p = 0.002) and the 
difference in the C4a levels obtained before and 
after protamine infusion (r = 0.33, p = 0.003). In 
contrast to the positive correlation between comple- 
ment activation by heparin-protamine interaction 
and shunt fractions, no correlation was seen be- 
tween the shunt fractions and the alternative path- 
way complement activation occurring during CPB, 
as measured by the C3a levels at the end of CPB but 
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before protamine administration (r = 0.078 for 
shunt fraction at 6 to 8 hours and r = 0.079 for shunt 
fraction at 16 to 18 hours). 
Discussion 
The present study shows that patients with heterozy- 
gous C4A null phenotype have more activation of the 
classic complement pathway after protamine adminis- 
tration than those with other C4 phenotypes. It also 
shows that heparin-protamine complexes make a sub- 
stantial contribution to complement activation during 
cardiac operations and that this complement activa- 
tion is associated with pathophysiologic effects as 
judged by pulmonary shunt fractions. 
Heparin-protamine complexes activate comple- 
ment by the classic pathway. 2-5' 13 Although consid- 
erable information about heparin and protamine 
individually is available in the literature, much less is 
known about the configuration, size, composition, 
and fate of heparin-protamine complexes. Because 
of their charge, they may adsorb or bind to different 
blood components. Previous studies have demon- 
strated the presence of immunoglobulins in the 
matrix of heparin-protamine complexes. 5' 14 In vitro 
studies also show that the immunoglobulins bound 
to heparin-protamine complexes enhance the result- 
ing complement activation, s However, the role of 
activated C4 binding in subsequent clearance of 
these complexes i not known. Animal studies have 
shown clearance of heparin-protamine complexes in 
the liver, 15 but whether they first bind to red cell 
complement receptors is unknown. 
The fourth component of complement plays an 
important role not only in the classic pathway of 
complement activation, but also in the clearance of 
the activating complexes. Its two isotypes, C4A and 
C4B, differ in their binding characteristics after 
activation. Activated C4A binds more effectively to 
immune complexes and plays an important role in 
their clearance, whereas activated C4B has more 
affinity for red cell membranes. 8 Another notewor- 
thy feature of C4 is the remarkable incidence of null 
alleles. Awdeh and Alper, 7 in their study of 100 
randomly selected white persons, found 20 subjects 
with a single C4A null allele (our AOBB designa- 
tion). Eighteen of our 79 patients had C4A null 
allele. In individuals with normal expression of both 
C4 isotypes (AABB group), the ratio of C4A and 
C4B is approximately 1. Lack of expression of one 
allele of C4A or C4B isotype (AOBB or AAB0) 
would reduce the expression of C4A or C4B by 
approximately half. 9 If C4A plays as important a 
role in clearance of heparin-protamine complexes as 
it does for immune complexes, then C4A null phe- 
notype can have a significant effect on complement 
activation by heparin-protamine complexes. 
In our study, the effect of C4A null allele was 
increased complement activation of the classic path- 
way resulting from heparin-protamine i teraction in 
comparison with the group with normal phenotype 
and that with C4B null allele. Although the C4A null 
group also had a greater increase in C3a levels after 
protamine than the other two groups, this difference 
did not reach statistical significance on multiple 
comparison tests. Because the level of C3a reflects 
activation of both the alternative and the classic 
pathways, it is less sensitive than C4a to changes 
exclusively affecting the classic pathway. 
One explanation for the increased complement 
activation by heparin-protamine complexes in pa- 
tients with C4A null allele could be the reduced 
clearance of these complexes. With the reduced 
C4A subcomponent, less activated C4 may be bound 
to the heparin-protamine complexes or to its other 
attached proteins. Thus their clearance, which de- 
pends on activated C4 (C4b) and C3 (C3b) binding, 
is reduced. This reduced clearance may allow the 
heparin-protamine complexes to stay in circulation, 
thereby activating more complement and generating 
more C4a and C3a. This paradox of increased fluid 
phase complement activation with decreased bind- 
ing of activated components has been shown to 
occur with some immune complexes. 16
The role and effectiveness of complement activa- 
tion by heparin-protamine complexes in producing 
adverse effects is the subject of controversy. The 
reason is that protamine itself may induce transient 
acute hemodynamic changes 17 and also may pro- 
duce allergic reactions. TM Although complement ac- 
tivation by heparin-protamine complexes has been 
recognized, the relative contribution of this activa- 
tion in producing pathophysiologie effects has not 
been addressed in most studies. It is necessary that 
complement cascade proceed beyond C3 activation 
if a particular mechanism of complement activation 
is to be deemed significant. Although C3a and C4a 
are useful markers of in vivo complement activation, 
the mediation of inflammation occurs mainly by 
C5a, a complement split product generated further 
along the complement cascade. 19 The value of fluid 
phase measurement of this extremely potent vaso- 
active peptide to gauge in vivo complement activa- 
tion is negated by its rapid binding to receptors on 
neutrophils and monocytes. 2° However, it can be 
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measured to indicate complement activation in vitro 
when leukocyte-free plasma or serum is used in 
experimental manipulations. In our previous stud- 
ies, C5a could indeed be generated uring comple- 
ment activation induced by the heparin-protamine 
complex in whole human serum when red cells were 
present in the reaction mixture. 13 
The present study shows that complement activa- 
tion by heparin-protamine complexes has delayed 
pathophysiologic consequences in lung function that 
are evident even 16 to 18 hours after the operation. 
In a study by Ranucci and associates, 21 pulmonary 
shunt fraction was judged to be the best index of 
determining the lung dysfunction after cardiac op- 
erations. They also noted that in their patient pop- 
ulation, free of preoperative lung dysfunction, 
changes in shunt fraction did not result in delay of 
extubation or discharge from the intensive care unit. 
As in their study, our patient population was se- 
lected to have normal preoperative pulmonary sta- 
tus and only one of our patients required more than 
24 hours of intubation. However, as these authors 
point out, the observed ifferences in shunt fractions 
could potentially result in a different clinical course 
in patients with preexisting lung dysfunction. 
There are some caveats in the interpretations of
the present study. We did not perform deoxyribo- 
nucleic acid analysis, and we inferred the genotype 
from phenotypic studies. However, the reduction in 
the relative concentration of a particular C4 type, 
identified by our phenotypic studies, is probably of 
pathophysiologic relevance, as discussed here. We 
cannot exclude the possibility that other associated 
genetic differences may also contribute to the dif- 
ferences Seen. We also did not measure the activa- 
tion of the terminal attack complex. Although we 
detected an association between the postoperative 
shunt fractions and C4a levels generated by prota- 
mine interaction with heparin, the differences in 
shunt fractions among patients could be due to 
postoperative factors not measured in our study. 
Although a probable explanation for the differ- 
ences in complement activation of the classic path- 
way between patients of different C4 isotypes is the 
reduced clearance of heparin-protamine complexes, 
the present study did not measure their clearance. 
Future studies specifically investigating the clear- 
ance of heparin-protamine complexes in patients 
with different C4 isotypes are warranted. Annually, 
in excess of 500,000 patients worldwide have hepa- 
rin-protamine complexes formed in vivo after CPB, 
and very little is known about the fate of these 
complexes once they are formed. 
We express our sincere gratitude to Deborah M. Bagley 
of the Center for Blood Research, Boston, Mass., for 
providing the reference plasma for C4 typing, as well as 
for invaluable technical advice. We also acknowledge Ms. 
Judith Colby and Mr. Edward Johnson for technical 
assistance and Robert Dunford, MA, for statistical dvice. 
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